Georgia Research Alliance

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

EarliTec Diagnostics is a digital health company focused on the early identification and treatment of autism spectrum disorder (ASD) and related disabilities in children. Developed by researchers from Children's Healthcare of Atlanta, Emory University School of Medicine, and Yale University, the company is at the forefront of creating biomarkers that enhance understanding of children's perspectives. EarliTec's innovative technology includes an investigational device that employs dynamic quantification of social-visual engagement (DQSVE) to analyze subtle looking behaviors that are often unnoticed by the naked eye. This advanced approach enables parents, healthcare providers, and caregivers to deliver personalized and timely therapeutic interventions tailored to individual needs.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

TendoNova is a medical technology company specializing in the development and manufacture of devices for minimally invasive orthopedic procedures. Its primary product is a surgical tool designed to assist in percutaneous tenotomy under ultrasound guidance, allowing clinicians to address tendon injuries and pain in an office-based setting. The company's offerings are customizable to individual patient needs without incurring significant additional costs.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Aviabiotic creates probiotics for integrated poultry companies. The probiotic, genetically engineered for thermostability, elimination of antibiotic resistance, and dependence on corn sugar (to protect the environment from recombinant DNA after it has left the chicken), will produce eicosapentanoic acid, a heart-healthy, Omega-3 fatty acid. Genetically engineered Bacillus subtilisspores in the chicken’s small intestine convert conventional poultry feed into helpful Omega-3 fatty acids. While currently in the concept stage, Aviabiotic has the tools to create a functional prototype for further testing purposes.

Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse model in the next phase of development. This technique, the passive administration of antibodies, importantly does not require a functioning immune response, making this ideally suited to immunocompromised patients needing protection from this bacterial pathogen.

AngioCloud is a technology company that offers cloud-based 3D imaging software specifically designed for analyzing vascular images. This innovative platform enables medical professionals to share high-quality 3D images seamlessly across various connected devices, including desktops and mobile phones. By facilitating collaboration on vascular cases, AngioCloud's software enhances the capabilities of surgeons in areas such as diagnosis, pre-surgical planning, and medical device selection. The technology supports e-consults and clinical decision-making, ultimately allowing for more precise and efficient surgical processes.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

BioData Consortium builds a third-party platform to aggregate and distribute anonymized, high quality-clinical data. This professionally curated data can be used to train artificial intelligence and deep learning technology, improving outcomes and driving down costs in radiology. Developed by radiologists and data professionals, BDC aims to be the largest repository of the highest-quality data available to medical technology researchers. The company is experienced in following HIPAA guidelines and working with federally regulated confidential data. BioData Consortium clients include leading research hospitals and healthcare provider networks.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

PNP Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. Established in 2000 and headquartered in Birmingham, Alabama, the company utilizes a proprietary platform based on the selective expression of E. coli purine nucleoside phosphorylase. This patented enzyme facilitates the activation of various nucleoside prodrugs, leading to the production of active metabolites that exhibit significant anti-tumor activity. PNP Therapeutics aims to enhance cancer treatment by directly targeting tumor cells within a controlled environment, thereby improving patient outcomes.

TendoNova is a medical technology company specializing in the development and manufacture of devices for minimally invasive orthopedic procedures. Its primary product is a surgical tool designed to assist in percutaneous tenotomy under ultrasound guidance, allowing clinicians to address tendon injuries and pain in an office-based setting. The company's offerings are customizable to individual patient needs without incurring significant additional costs.

HAWA Therapeutics creates a novel treatment for muscle strain, damage, and dystrophy stimulating muscle stem cell functions. The treatment involves injecting HIF2ai inhibitors into the muscle, but the company is also exploring topical and oral approaches. Moderate and severe muscle strains can cause immense pain, causing people to be out of work for long periods of time. Treatment options are limited to physical therapy, surgery, and a host of short-term drugs such as anti-inflammatories. Severe strains often heal incompletely, making people susceptible to further injury. HAWA’s HIF2Ai technology accelerates initial recovery and reduces recurrent injuries by preventing the formation of scar tissue.

Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists. The drugs Pyrefin is testing have myriad potential uses, including treatment for epileptic seizures. Rodent trials have shown efficacy in treatment for seizure-induced brain injury, endometriosis, and osteoarthritis without behavioral or organ toxicity after 30 days. Phase 1A of GRA’s venture development support focused Pyrefin’s team on prioritizing the clinical use of its treatment.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the development of real-time cellular activity monitors for drug discovery and biological research. The company focuses on providing innovative systems that enable researchers in academic institutions and pharmaceutical companies to conduct continuous and non-invasive analysis of cellular behavior. Its flagship technology, RESIPHER, utilizes proprietary high-resolution optical oxygen sensors to measure oxygen consumption in standard multi-well plates. This tool streams real-time data to a user-friendly web application, allowing researchers to gain valuable insights into the cellular environment directly from the incubator, thereby enhancing the efficiency of cell culture experiments.

Kodikaz Therapeutic Solutions is a biotechnology company focused on developing targeted cancer therapies that aim to provide durable cures while minimizing side effects associated with traditional treatments. The company has created the Zip-Code™ Technology platform, a pioneering cell-specific delivery system designed for a wide range of gene therapy applications. This innovative platform leverages endogenous human mechanisms to avoid the complications associated with viral delivery methods. By translating previously unknown cell-recognition and genomic integration mechanisms, Kodikaz enables the development of cell-specific gene transfer technologies tailored for various cancers, including pancreatic, myeloma, and colorectal. Through its research and development efforts, the company generates both in-vitro and in-vivo data to support the advancement of curative therapies in oncology.

BioData Consortium builds a third-party platform to aggregate and distribute anonymized, high quality-clinical data. This professionally curated data can be used to train artificial intelligence and deep learning technology, improving outcomes and driving down costs in radiology. Developed by radiologists and data professionals, BDC aims to be the largest repository of the highest-quality data available to medical technology researchers. The company is experienced in following HIPAA guidelines and working with federally regulated confidential data. BioData Consortium clients include leading research hospitals and healthcare provider networks.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Sequegenics is a technology company that specializes in genetic analysis through its fully automated cloud platform. The company has developed a novel approach utilizing augmented low-pass long-read next-generation sequencing (NGS) to identify structural variants and other complex types of genetic variations. By processing long-read NGS raw data, Sequegenics enables clients to efficiently minimize the time and cost associated with variant calling, while also enhancing turnaround time and scalability. This innovative platform supports researchers and healthcare professionals in their efforts to better understand genetic variations, ultimately contributing to advancements in genomic medicine.

Abby Med operates a pharmaceutical company that specializes in developing drugs for treating cancer.

TendoNova is a medical technology company specializing in the development and manufacture of devices for minimally invasive orthopedic procedures. Its primary product is a surgical tool designed to assist in percutaneous tenotomy under ultrasound guidance, allowing clinicians to address tendon injuries and pain in an office-based setting. The company's offerings are customizable to individual patient needs without incurring significant additional costs.

Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists. The drugs Pyrefin is testing have myriad potential uses, including treatment for epileptic seizures. Rodent trials have shown efficacy in treatment for seizure-induced brain injury, endometriosis, and osteoarthritis without behavioral or organ toxicity after 30 days. Phase 1A of GRA’s venture development support focused Pyrefin’s team on prioritizing the clinical use of its treatment.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the development of real-time cellular activity monitors for drug discovery and biological research. The company focuses on providing innovative systems that enable researchers in academic institutions and pharmaceutical companies to conduct continuous and non-invasive analysis of cellular behavior. Its flagship technology, RESIPHER, utilizes proprietary high-resolution optical oxygen sensors to measure oxygen consumption in standard multi-well plates. This tool streams real-time data to a user-friendly web application, allowing researchers to gain valuable insights into the cellular environment directly from the incubator, thereby enhancing the efficiency of cell culture experiments.

Cognition Medical Corp. is a medical device company based in Cambridge, Massachusetts, specializing in the development of innovative solutions for acute stroke patients. The company has designed a device that effectively removes blood clots from the brain without the need for surgical intervention, utilizing minimally invasive techniques that navigate through catheters within the blood vessels. This technology not only enhances the safety and efficiency of the clot retrieval procedure but also protects the brain from potential over-oxygenation that can occur after unblocking vessels. Founded in 2012, Cognition Medical combines expertise in engineering, biology, and interventional medicine to create devices aimed at reducing brain damage and improving patient outcomes in stroke care.

Aviabiotic creates probiotics for integrated poultry companies. The probiotic, genetically engineered for thermostability, elimination of antibiotic resistance, and dependence on corn sugar (to protect the environment from recombinant DNA after it has left the chicken), will produce eicosapentanoic acid, a heart-healthy, Omega-3 fatty acid. Genetically engineered Bacillus subtilisspores in the chicken’s small intestine convert conventional poultry feed into helpful Omega-3 fatty acids. While currently in the concept stage, Aviabiotic has the tools to create a functional prototype for further testing purposes.

Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called “stroma,” which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. Early testing of the company’s targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

Diasyst is a healthcare technology company that specializes in chronic disease management, particularly focusing on diabetes. It offers a Medication Intelligence solution that enables healthcare providers to make timely and effective treatment decisions. The company's application collects and analyzes critical patient information in real-time using proprietary algorithms, providing tailored medication intervention recommendations. This approach is grounded in an extensive knowledge base comprising clinical guidelines, drug labels, research studies, and best practices developed through decades of research at Emory University and the VA. By leveraging artificial intelligence, Diasyst aims to enhance clinical outcomes, reduce the risk of complications for patients, and optimize overall care, thereby improving engagement and satisfaction among healthcare teams and patients alike.

Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse model in the next phase of development. This technique, the passive administration of antibodies, importantly does not require a functioning immune response, making this ideally suited to immunocompromised patients needing protection from this bacterial pathogen.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing innovative therapies for viral diseases. Founded in 2018 by Abel De La Rosa, Douglas Mayers, and Idean Marvasty, the company is dedicated to addressing the needs of patients infected with Hepatitis B and Hepatitis D viruses. Its lead product, ATI-2173, is an oral drug candidate aimed at providing a potentially curative treatment for Hepatitis B virus infections. With a leadership team that brings a wealth of experience, Antios Therapeutics is committed to advancing its therapeutic solutions in the field of viral diseases.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

Centizyme develops a nanoparticle-based treatment for severe asthma. The therapy, called GeneRegs, is made from gold nanoparticles, coated with an enzyme that directly targets a protein that causes asthma symptoms. Because the gold nanoparticles are so small, they can be safely inhaled, delivering targeted therapy directly to the lungs – unlike oral steroids, which attack that same protein throughout the entire body. The systemic approach of steroids suppresses the immune system and causes other negative side effects, including osteoporosis and diabetes. The targeted approach of GeneRegs makes it a promising therapy that could provide a better and safer alternative to oral steroids and improve outcomes for approximately 1.5 million patients with severe asthma.

BioPace develops a hardware-free “biological pacemaker” to complement or replace traditional implantable devices. The technology uses mRNA-mediated gene transfer – called Tbx18 transduction – to deliver a human gene that dictates the formation of pacemaker tissue. When TBX18 is re-expressed within an adult human, the hallmark features of native pacemaker tissue in the heart are reproduced. When combined with a small molecule, A83-01, TBX18-induced pacemaker cells have proven durable. BioPace’s published data demonstrates the feasibility of the concept in small and large animal models. As of spring 2021, the company was working to further validate the concept for clinical application.

PNP Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. Established in 2000 and headquartered in Birmingham, Alabama, the company utilizes a proprietary platform based on the selective expression of E. coli purine nucleoside phosphorylase. This patented enzyme facilitates the activation of various nucleoside prodrugs, leading to the production of active metabolites that exhibit significant anti-tumor activity. PNP Therapeutics aims to enhance cancer treatment by directly targeting tumor cells within a controlled environment, thereby improving patient outcomes.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the development of real-time cellular activity monitors for drug discovery and biological research. The company focuses on providing innovative systems that enable researchers in academic institutions and pharmaceutical companies to conduct continuous and non-invasive analysis of cellular behavior. Its flagship technology, RESIPHER, utilizes proprietary high-resolution optical oxygen sensors to measure oxygen consumption in standard multi-well plates. This tool streams real-time data to a user-friendly web application, allowing researchers to gain valuable insights into the cellular environment directly from the incubator, thereby enhancing the efficiency of cell culture experiments.

PDx Scan develops a way to assess the degeneration that comes from Parkinson’s disease using a magnetic resonance imaging (MRI) scan. The approach offers significant advantages over the only existing neuro-imaging technique approved by the FDA for diagnosing Parkinson’s. The current technique is quite costly, and the images it creates aren’t detailed enough to assess how well a Parkinson’s treatment being tested in clinical trials is working. PDx Scan designed a machine-learning algorithm to work hand-in-hand with a multi-contrast MRI scan. It would be more affordable than the current technique, and it would provide more useful information to researchers in clinical trials. Initially, the startup is making this technology available to hospitals and healthcare systems to aid in various clinical diagnoses and plans of care. PDx Scan is aiming to expand to clinical trials for Parkinson’s treatment, where the technology can be used to select participants in the trial and assess their progress.

BioPace develops a hardware-free “biological pacemaker” to complement or replace traditional implantable devices. The technology uses mRNA-mediated gene transfer – called Tbx18 transduction – to deliver a human gene that dictates the formation of pacemaker tissue. When TBX18 is re-expressed within an adult human, the hallmark features of native pacemaker tissue in the heart are reproduced. When combined with a small molecule, A83-01, TBX18-induced pacemaker cells have proven durable. BioPace’s published data demonstrates the feasibility of the concept in small and large animal models. As of spring 2021, the company was working to further validate the concept for clinical application.

RePredix develops an acuity algorithm to predict and warn patients of potential heart failure. Its initial algorithm proved that heart failure can be diagnosed using wristband data.

Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called “stroma,” which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. Early testing of the company’s targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.

Covanos is a development-stage medical technology company focused on the diagnosis and treatment of cardiac and vascular diseases. The company specializes in creating next-generation digital medical diagnostic software that leverages advanced mathematical methods and computational fluid dynamics. Its innovative platform evaluates coronary obstructions by analyzing CT angiography images of the heart, providing crucial clinical information to physicians in near real-time. This technology enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance patient outcomes through its cutting-edge diagnostic solutions.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Cognition Medical Corp. is a medical device company based in Cambridge, Massachusetts, specializing in the development of innovative solutions for acute stroke patients. The company has designed a device that effectively removes blood clots from the brain without the need for surgical intervention, utilizing minimally invasive techniques that navigate through catheters within the blood vessels. This technology not only enhances the safety and efficiency of the clot retrieval procedure but also protects the brain from potential over-oxygenation that can occur after unblocking vessels. Founded in 2012, Cognition Medical combines expertise in engineering, biology, and interventional medicine to create devices aimed at reducing brain damage and improving patient outcomes in stroke care.

Centizyme develops a nanoparticle-based treatment for severe asthma. The therapy, called GeneRegs, is made from gold nanoparticles, coated with an enzyme that directly targets a protein that causes asthma symptoms. Because the gold nanoparticles are so small, they can be safely inhaled, delivering targeted therapy directly to the lungs – unlike oral steroids, which attack that same protein throughout the entire body. The systemic approach of steroids suppresses the immune system and causes other negative side effects, including osteoporosis and diabetes. The targeted approach of GeneRegs makes it a promising therapy that could provide a better and safer alternative to oral steroids and improve outcomes for approximately 1.5 million patients with severe asthma.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

Centizyme develops a nanoparticle-based treatment for severe asthma. The therapy, called GeneRegs, is made from gold nanoparticles, coated with an enzyme that directly targets a protein that causes asthma symptoms. Because the gold nanoparticles are so small, they can be safely inhaled, delivering targeted therapy directly to the lungs – unlike oral steroids, which attack that same protein throughout the entire body. The systemic approach of steroids suppresses the immune system and causes other negative side effects, including osteoporosis and diabetes. The targeted approach of GeneRegs makes it a promising therapy that could provide a better and safer alternative to oral steroids and improve outcomes for approximately 1.5 million patients with severe asthma.

Covanos is a development-stage medical technology company focused on the diagnosis and treatment of cardiac and vascular diseases. The company specializes in creating next-generation digital medical diagnostic software that leverages advanced mathematical methods and computational fluid dynamics. Its innovative platform evaluates coronary obstructions by analyzing CT angiography images of the heart, providing crucial clinical information to physicians in near real-time. This technology enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance patient outcomes through its cutting-edge diagnostic solutions.

Abby Med operates a pharmaceutical company that specializes in developing drugs for treating cancer.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Reservoir is a Greece-based company founded in 2016 that specializes in wireless irrigation solutions for landscapers and horticulturists. The company offers an innovative product called Reservoir Spoke, which allows for the management of irrigation systems via smartphone or computer from any location globally. This technology simplifies the installation and maintenance of irrigation systems by eliminating the need for traditional hardware components, such as wires and controllers. With Reservoir Spoke, landscapers can easily add new valves without extensive wiring, while growers benefit from automated irrigation with reduced risk of lightning damage.

MicroBplex is a biotechnology company dedicated to developing a diagnostic platform aimed at identifying microbial infections, with a particular emphasis on pneumonia and influenza. The company specializes in the detection of nascent antibody-secreting cells (ASCs) that are present in a patient's blood during acute infections. By utilizing a matrix of newly synthesized antibodies, MicroBplex's technology enables early detection and assessment of therapeutic effectiveness, as well as the ability to distinguish between new and prior infections. This innovative approach provides healthcare professionals with essential diagnostic information, facilitating timely and effective therapeutic intervention.

TendoNova is a medical technology company specializing in the development and manufacture of devices for minimally invasive orthopedic procedures. Its primary product is a surgical tool designed to assist in percutaneous tenotomy under ultrasound guidance, allowing clinicians to address tendon injuries and pain in an office-based setting. The company's offerings are customizable to individual patient needs without incurring significant additional costs.

RePredix develops an acuity algorithm to predict and warn patients of potential heart failure. Its initial algorithm proved that heart failure can be diagnosed using wristband data.

NanoV Therapeutics develops a novel-mechanism anti-cancer drug. The compound, known as VPOA-6, has demonstrated high effectiveness in inhibiting tumor growth and combating a wide variety of cancers, with much less cytotoxicity than other leading drugs (Cisplatin, one of the most common first-line anti-cancer treatments). NanoV intends to use their newly discovered mechanism, utilizing redox catalysis, to develop a new class of anti-cancer agents to bring life-saving treatment to cancer patients. With drug resistance becoming a more pronounced obstacle to cancer treatment, novel mechanisms that demonstrate efficacy and safety have the potential to earn a large market. VPOA-6 significantly suppresses a wide range of cancers, including multi-drug resistant types. The synthesis and purification of VPOA-6 are readily accomplished in eco-friendly circumstances, requiring no toxic waste, and costing significantly less than existing cancer drugs.

Covanos is a development-stage medical technology company focused on the diagnosis and treatment of cardiac and vascular diseases. The company specializes in creating next-generation digital medical diagnostic software that leverages advanced mathematical methods and computational fluid dynamics. Its innovative platform evaluates coronary obstructions by analyzing CT angiography images of the heart, providing crucial clinical information to physicians in near real-time. This technology enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance patient outcomes through its cutting-edge diagnostic solutions.

BioPace develops a hardware-free “biological pacemaker” to complement or replace traditional implantable devices. The technology uses mRNA-mediated gene transfer – called Tbx18 transduction – to deliver a human gene that dictates the formation of pacemaker tissue. When TBX18 is re-expressed within an adult human, the hallmark features of native pacemaker tissue in the heart are reproduced. When combined with a small molecule, A83-01, TBX18-induced pacemaker cells have proven durable. BioPace’s published data demonstrates the feasibility of the concept in small and large animal models. As of spring 2021, the company was working to further validate the concept for clinical application.

Sanguina is a medical device and wellness tool company that specializes in innovative point-of-care diagnostics. It is currently focused on launching its first product, AnemoCheck Mobile, which is a groundbreaking smartphone application designed for the non-invasive tracking of hemoglobin levels. This app eliminates the need for painful blood draws by utilizing a color-based testing method, primarily aimed at screening for anemia. Sanguina's technology enables users to easily and effectively monitor their hemoglobin levels, enhancing accessibility to important health information.

Nutrivert is a biotechnology company focused on developing postbiotics as an alternative to traditional antibiotics in livestock. The company's innovative formulation acts as a feed additive that enhances feed conversion efficiency, allowing livestock producers to achieve better output from their animals. By selectively targeting bacteria susceptible to antibiotics, Nutrivert's postbiotics help control bacterial diseases in livestock, thereby improving overall health and productivity. This approach not only supports animal welfare but also addresses the growing need for sustainable alternatives in livestock management.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

Diasyst is a healthcare technology company that specializes in chronic disease management, particularly focusing on diabetes. It offers a Medication Intelligence solution that enables healthcare providers to make timely and effective treatment decisions. The company's application collects and analyzes critical patient information in real-time using proprietary algorithms, providing tailored medication intervention recommendations. This approach is grounded in an extensive knowledge base comprising clinical guidelines, drug labels, research studies, and best practices developed through decades of research at Emory University and the VA. By leveraging artificial intelligence, Diasyst aims to enhance clinical outcomes, reduce the risk of complications for patients, and optimize overall care, thereby improving engagement and satisfaction among healthcare teams and patients alike.

Sequegenics is a technology company that specializes in genetic analysis through its fully automated cloud platform. The company has developed a novel approach utilizing augmented low-pass long-read next-generation sequencing (NGS) to identify structural variants and other complex types of genetic variations. By processing long-read NGS raw data, Sequegenics enables clients to efficiently minimize the time and cost associated with variant calling, while also enhancing turnaround time and scalability. This innovative platform supports researchers and healthcare professionals in their efforts to better understand genetic variations, ultimately contributing to advancements in genomic medicine.

Urjanet, Inc. is a company that specializes in providing a cloud-based platform for automated access to utility data. Founded in 2009 and headquartered in Atlanta, Georgia, with an additional location in Chennai, India, Urjanet connects directly to utility providers to acquire and normalize utility bills and interval data. Its offerings include automated access to utility bill data across various utilities, granular measurements of energy consumption, and advanced metering infrastructure data without requiring additional hardware or software. The platform also features capabilities for weather data analysis and alerts for billing and consumption anomalies. Urjanet's solutions are designed to improve business intelligence, energy management, accounting, and procurement processes for organizations, enabling them to enhance financial performance, energy efficiency, and sustainability.

Sophia Bioscience develops new pharmaceutical treatments for early and metastatic cancers. It aims to increase the effectiveness of established drugs while lowering their required dosage and minimizing side effects. Sophia Bioscience also works to improve the drug development process, shortening the time to develop and significantly lowering associated costs. The company is currently focused on treating prostate cancer. The first drug candidate Sophia has put forward uses an independent anti-tumor chemotype, HDACi, and exploits prostate tumor androgen receptors (AR) for a more selective delivery than existing drugs. By exploiting these receptors, the drug resolves the issue of insufficient accumulation in the tumor and localizes the effects of the HDACi.

Covanos is a development-stage medical technology company focused on the diagnosis and treatment of cardiac and vascular diseases. The company specializes in creating next-generation digital medical diagnostic software that leverages advanced mathematical methods and computational fluid dynamics. Its innovative platform evaluates coronary obstructions by analyzing CT angiography images of the heart, providing crucial clinical information to physicians in near real-time. This technology enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance patient outcomes through its cutting-edge diagnostic solutions.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Neurotrack Technologies, Inc., established in 2012 and headquartered in Redwood City, California, specializes in digital health solutions for early detection and ongoing monitoring of cognitive impairment, particularly Alzheimer's and other dementias. The company offers a computer-based cognitive test, validated clinically and guided by patients, which can be administered in clinics or at home, fitting various workflows. Neurotrack's proprietary technology has been recognized with 11 patents and is registered as an FDA Class II medical device. The company has published 27 peer-reviewed papers, demonstrating its commitment to scientific rigor and innovation in transforming dementia diagnosis and management.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

CellectCell is a development-stage company dedicated to providing novel cell isolation tools for life science research

RePredix develops an acuity algorithm to predict and warn patients of potential heart failure. Its initial algorithm proved that heart failure can be diagnosed using wristband data.

MoQuality Inc. is a technology company founded in 2014 and headquartered in Atlanta, Georgia, that specializes in artificial intelligence-driven mobile testing solutions. The company focuses on enhancing the application development process by providing tools that allow developer teams to create, run, and maintain tests efficiently. MoQuality's flagship product, Barista, offers a scriptless test automation experience, leveraging AI to generate user-centric test scenarios for mobile applications. This platform enables developers to conduct comprehensive end-to-end UI testing across various devices and operating systems, ensuring that applications are thoroughly vetted before reaching consumers. By streamlining the testing process, MoQuality aims to help developers deliver higher-quality apps and improve overall user experiences.

MicroBplex is a biotechnology company dedicated to developing a diagnostic platform aimed at identifying microbial infections, with a particular emphasis on pneumonia and influenza. The company specializes in the detection of nascent antibody-secreting cells (ASCs) that are present in a patient's blood during acute infections. By utilizing a matrix of newly synthesized antibodies, MicroBplex's technology enables early detection and assessment of therapeutic effectiveness, as well as the ability to distinguish between new and prior infections. This innovative approach provides healthcare professionals with essential diagnostic information, facilitating timely and effective therapeutic intervention.

Diasyst is a healthcare technology company that specializes in chronic disease management, particularly focusing on diabetes. It offers a Medication Intelligence solution that enables healthcare providers to make timely and effective treatment decisions. The company's application collects and analyzes critical patient information in real-time using proprietary algorithms, providing tailored medication intervention recommendations. This approach is grounded in an extensive knowledge base comprising clinical guidelines, drug labels, research studies, and best practices developed through decades of research at Emory University and the VA. By leveraging artificial intelligence, Diasyst aims to enhance clinical outcomes, reduce the risk of complications for patients, and optimize overall care, thereby improving engagement and satisfaction among healthcare teams and patients alike.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

NovAb operates as a biotechnology company. The company commercializes monoclonal antibody technology. This organization primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, Accounting, Research, and Management Services sector.

Diasyst is a healthcare technology company that specializes in chronic disease management, particularly focusing on diabetes. It offers a Medication Intelligence solution that enables healthcare providers to make timely and effective treatment decisions. The company's application collects and analyzes critical patient information in real-time using proprietary algorithms, providing tailored medication intervention recommendations. This approach is grounded in an extensive knowledge base comprising clinical guidelines, drug labels, research studies, and best practices developed through decades of research at Emory University and the VA. By leveraging artificial intelligence, Diasyst aims to enhance clinical outcomes, reduce the risk of complications for patients, and optimize overall care, thereby improving engagement and satisfaction among healthcare teams and patients alike.

Sanguina is a medical device and wellness tool company that specializes in innovative point-of-care diagnostics. It is currently focused on launching its first product, AnemoCheck Mobile, which is a groundbreaking smartphone application designed for the non-invasive tracking of hemoglobin levels. This app eliminates the need for painful blood draws by utilizing a color-based testing method, primarily aimed at screening for anemia. Sanguina's technology enables users to easily and effectively monitor their hemoglobin levels, enhancing accessibility to important health information.

Sequegenics is a technology company that specializes in genetic analysis through its fully automated cloud platform. The company has developed a novel approach utilizing augmented low-pass long-read next-generation sequencing (NGS) to identify structural variants and other complex types of genetic variations. By processing long-read NGS raw data, Sequegenics enables clients to efficiently minimize the time and cost associated with variant calling, while also enhancing turnaround time and scalability. This innovative platform supports researchers and healthcare professionals in their efforts to better understand genetic variations, ultimately contributing to advancements in genomic medicine.

Codoxo, formerly known as Fraudscope, is a company dedicated to enhancing the affordability and effectiveness of the healthcare system. It has developed a Forensic AI Platform that employs a patented algorithm to swiftly identify issues and suspicious activities within healthcare plans, surpassing traditional detection methods. This technology facilitates smart investigation and fraud detection, allowing investigators and analysts to gain valuable insights and conduct comprehensive investigations of questionable claims. By utilizing advanced AI-based capabilities, Codoxo aims to ensure that healthcare resources are allocated to genuine patient care, ultimately contributing to a more efficient healthcare environment.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

Covanos is a development-stage medical technology company focused on the diagnosis and treatment of cardiac and vascular diseases. The company specializes in creating next-generation digital medical diagnostic software that leverages advanced mathematical methods and computational fluid dynamics. Its innovative platform evaluates coronary obstructions by analyzing CT angiography images of the heart, providing crucial clinical information to physicians in near real-time. This technology enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance patient outcomes through its cutting-edge diagnostic solutions.

Accuitis, Inc. is a pre-clinical-stage biopharmaceutical company focused on acquiring, developing, and marketing innovative pharmaceuticals for niche, orphan, and underserved disease states. Founded in 2011, the company is headquartered in Alpharetta, Georgia. Accuitis specializes in the development of drug therapies for conditions such as rosacea and other topical skin diseases, as well as therapeutics for skin aging, acne, and dry eye. Through its targeted approach, Accuitis aims to address significant unmet medical needs in these areas.

TendoNova is a medical technology company specializing in the development and manufacture of devices for minimally invasive orthopedic procedures. Its primary product is a surgical tool designed to assist in percutaneous tenotomy under ultrasound guidance, allowing clinicians to address tendon injuries and pain in an office-based setting. The company's offerings are customizable to individual patient needs without incurring significant additional costs.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

CellectCell is a development-stage company dedicated to providing novel cell isolation tools for life science research

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

MetCure Therapeutics is a biotechnology company that develops new drugs to treat metastatic cancer. It has developed a prostate cancer cell line that exhibits the characteristics of malignant, chemo-resistant human cancer cells. Using its proprietary high-throughput screening platform, MetCure is testing and identifying compounds that serve as effective drugs against these lethal cells. MetCure has identified LG1980 as one lead compound and outlined the mechanism LG1980 uses to attack prostate cancer cells. Other cancer stem cell inhibitors are also being explored.

LymphaTech, Inc. is a healthcare technology company based in Atlanta, Georgia, focused on the treatment and prevention of lymphedema. Founded in 2014, the company has developed an innovative 3D body scanning technology that enables healthcare professionals to diagnose lymphedema more effectively and promptly. The device measures limb circumference to create accurate three-dimensional models, allowing for the monitoring of geometric changes over time. This technology can be utilized both in clinical settings and at home, facilitating early detection of symptoms and enabling timely intervention. By providing an easy-to-use mobile platform powered by proprietary algorithms, LymphaTech aims to enhance the quality of life for patients, particularly breast cancer survivors, while meeting critical needs in the healthcare community.

CloudTags is a company that provides a digital platform designed to enhance the retail experience within physical stores. This platform enables retailers to track products that customers consider and collect email information from those who are not yet ready to make a purchase. By leveraging this data, CloudTags assists retailers in effectively reaching out to customers and gaining insights into their preferences and behaviors. The company's focus is on delivering a connected digital experience that integrates seamlessly into existing retail environments, thereby facilitating improved customer engagement and understanding.

NovAb operates as a biotechnology company. The company commercializes monoclonal antibody technology. This organization primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, Accounting, Research, and Management Services sector.

Abby Med operates a pharmaceutical company that specializes in developing drugs for treating cancer.

AlphaStem is a healthcare device manufacturer located in Mineral Wells, Texas. The company focuses on the design and production of cranial electrotherapy simulator devices, which are intended to treat conditions such as anxiety, insomnia, depression, and pain. These devices are tailored for use in medical facilities, physician offices, and in home settings, providing patients with accessible treatment options for their mental health and pain management needs. AlphaStem operates within the biotechnical research sector, emphasizing its commitment to innovation in healthcare technology.

RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of virus-related death for infants, particularly premature infants. Elderly people are also at risk from RSV.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.